KAER Biotherapeutics has been awarded a $2 million Phase 2 Small Business Innovation Research (SBIR) grant by the National Heart Lung and Blood Institute of the National Institutes of Health for development of a device based on its SUPRAER aerosol technology for delivery of surfactant to treat acute respiratory distress syndrome (ARDS), the company said.
KAER’s SUPRAER is designed to produce high concentration aerosols at up to 20 times the dose rate of currently marketed nebulizers, including viscous solutions and suspensions. The new grant is designed to develop the current bench version of SUPRAER into a medical device for the treatment of ARDS. The company is looking for partners for development of the technology for the treatment of other respiratory diseases.
Read the KAER Biotherapeutics press release.
